693287-78-4

Basic information

• Product Name: Hydrazinecarboxylic acid, (tetrahydro-4H-pyran-4-ylidene)-, 1,1-dimethylethyl
• Synonyms: Hydrazinecarboxylic acid, (tetrahydro-4H-pyran-4-ylidene)-, 1,1-dimethylethyl;2-(Tetrahydro-4H-pyran-4-ylidene)hydrazinecarboxylic acid 1,1-dimethylethyl ester;N'-(Tetrahydropyran-4-ylidene)hydrazinecarboxylic acid tert-butyl ester;t-Butyl 2(2H-pyran-4(3H,5H,6H)-ylidene)hydrazinecarboxylate;N-(Tetrahydro-pyran-4-ylidene)-hydrazinecarboxylic acid tert-butyl ester(WX684008)
• CAS NO: 693287-78-4
• Molecular Formula: C₁₀H₁₈N₂O₃
• Molecular Weight: 214.26152
• Product Categories: N-BOC
• Mol File: 693287-78-4.mol
• Article Data: 14

Chemical Properties

• Appearance: /
• Density: 1.14
• CAS DataBase Reference: Hydrazinecarboxylic acid, (tetrahydro-4H-pyran-4-ylidene)-, 1,1-dimethylethyl(CAS DataBase Reference)
• NIST Chemistry Reference: Hydrazinecarboxylic acid, (tetrahydro-4H-pyran-4-ylidene)-, 1,1-dimethylethyl(693287-78-4)
• EPA Substance Registry System: Hydrazinecarboxylic acid, (tetrahydro-4H-pyran-4-ylidene)-, 1,1-dimethylethyl(693287-78-4)

Safety Data

• Hazardous Substances Data: 693287-78-4(Hazardous Substances Data)

Upstream product

• 29943-42-8 Tetrahydro-4H-pyran-4-one 
• 870-46-2 t-butoxycarbonylhydrazine 

Downstream Products

• 1082745-70-7 C₁₂H₂₂N₂O₄ 
• 693287-79-5 N’-(tetrahydropyran-4-yl)hydrazinecarboxylic acid tert-butyl ester 
• 1247075-24-6 3-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-5-amine 
• 1548588-46-0 6-(phenoxymethyl)-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one 
• 1082745-50-3 5-amino-1-(tetrahydropyran-4-yl)-1H-pyrazole-4-carboxylic acid amide 
• 1082745-49-0 5-amino-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazole-4-carbonitrile 
• 1548588-87-9 6-[(2-chlorophenoxy)methyl]-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one 
• 693287-82-0 methyl 5-[(4-methylsulfonyl)phenyl]-1-(tetrahydro-2H-pyran-4-yl)pyrazole-3-carboxylate 
• 693287-83-1 [5-(4-methanesulfonyl-phenyl)-1-(tetrahydro-pyran-4-yl)-1H-pyrazol-3-yl]-methanol 
• 693287-81-9 methyl 5-(4-methylthiophenyl)-1-(tetrahydro-2H-pyran-4-yl)pyrazole-3-carboxylate 
• 116312-69-7 tetrahydro-2H-pyran-4-yl-hydrazine 

Relevant articles and documents

COMPOUNDS HAVING PDE9A INHIBITORY ACTIVITY, AND PHARMACEUTICAL USES THEREOF

The present invention provides a compound having a specific chemical structure and having PDE9A inhibitory activity, or a pharmaceutically acceptable salt thereof. The present invention provides a composition containing the compound or a pharmaceutically acceptable salt thereof. The present invention provides a pharmaceutical use, for treating or preventing PDE9A-related diseases, of the compound according to the present invention, a salt thereof, and a composition containing the compound or salt. The present invention also provides a method for treating or preventing PDE9A-related diseases, the method comprising administering an effective amount of the compound according to the present invention, a salt thereof, or a composition containing the compound or salt to a subject in need of treatment.

PYRAZOLOPYRAZINES ACTING ON CANCERS VIA INHIBITION OF CDK12

The present invention provides compounds of general formula (I) in which X, R1, R2 and R3 are as described and defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment and/or prophylaxis of diseases, in particular of hyperproliferative disorders such as cancer disorders, as a sole agent or in combination with other active ingredients.

PYRAZOLOPYRIMIDINES AS INHIBITORS OF GLUCOCORTICOID RECEPTOR TRANSLOCATION

Provided herein are compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful as modulators of Glucocorticoid Receptor (GR) translocation. Furthermore, the subject compounds and compositions are useful for the treatment of diseases involved in the hypothalamic-pituitary-adrenal (HPA) axis.